Insulet Corporation (NASDAQ:PODD) Receives $327.24 Average Target Price from Analysts

Shares of Insulet Corporation (NASDAQ:PODD) have been assigned a consensus rating of “Moderate Buy” from the twenty-four brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $327.2381.

Several equities research analysts recently commented on the company. Weiss Ratings raised Insulet from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Canaccord Genuity Group cut their price target on Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. Leerink Partners reduced their target price on Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Finally, Sanford C. Bernstein reduced their target price on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th.

Insulet Price Performance

NASDAQ:PODD opened at $167.53 on Friday. Insulet has a one year low of $158.35 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The stock has a market cap of $11.60 billion, a PE ratio of 47.87, a P/E/G ratio of 1.01 and a beta of 1.20. The stock has a 50 day moving average price of $214.88 and a 200 day moving average price of $266.12.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. During the same quarter last year, the firm earned $1.15 earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities research analysts expect that Insulet will post 6.27 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PODD. Larson Financial Group LLC raised its position in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet in the fourth quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in Insulet in the fourth quarter valued at $28,000. DV Equities LLC acquired a new stake in shares of Insulet in the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet in the fourth quarter valued at $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.